New pages

Jump to navigation Jump to search
New pages
Hide registered users | Hide bots | Show redirects

23 March 2025

  • 12:4112:41, 23 March 2025 Cefiderocol (hist | edit) [6,676 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid AfkhamiArdakani |genericName=Cefiderocol |aOrAn=a |drugClass=Siderophore Cephalosporin Antibiotic |indicationType=treatment |indication=Complicated Urinary Tract Infections (cUTIs), Hospital-Acquired Bacterial Pneumonia (HABP), and Ventilator-Associated Bacterial Pneumonia (VABP) in adult patients. |hasBlackBoxWarning=Yes |adverseReactions=Diarrhea​, Infusion site reactions​, Constipation​, Rash​, Candidiasis (including...")

21 March 2025

  • 00:4700:47, 21 March 2025 Zanubrutinib (hist | edit) [6,355 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Zanubrutinib |aOrAn=a |drugClass=Bruton's Tyrosine Kinase (BTK) Inhibitor |indicationType=treatment |indication=Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Waldenström's Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), and Follicular Lymphoma (FL) in adults. |adverseReactions=Decreased neutrophil count, Upper respiratory tract infection,...")

20 March 2025

  • 10:5610:56, 20 March 2025 Reblozyl (hist | edit) [5,813 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Luspatercept-aamt |aOrAn=an |drugClass=Erythroid Maturation Agent |indicationType=treatment |indication=anemia in adult patients. More specifically anemia due to Beta Thalassemia, Myelodysplastic Syndromes (MDS), MDS with Ring Sideroblasts (MDS-RS) or Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). |adverseReactions=Fatigue​, Headache​, Musc...")
  • 10:2010:20, 20 March 2025 Vadadustat (hist | edit) [19,544 bytes] Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=vadadustat |indicationType=treatment |indication=VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. |hasBlackBoxWarning=Yes |adverseReactions=*VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE) *Targeting a hemoglobin lev...")

18 March 2025

  • 20:5820:58, 18 March 2025 Danicopan (hist | edit) [29,524 bytes] Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=Danicopan |aOrAn=a |drugClass=medication |indicationType=treatment |indication=VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). |hasBlackBoxWarning=Yes |adverseReactions=*Serious Infections Caused by Encapsulated Bacteria *Hepatic Enzyme Increase *Hyperl...")
  • 20:3620:36, 18 March 2025 Ceftobiprole medocaril sodium (hist | edit) [36,115 bytes] Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=ceftobiprole medocaril sodium |aOrAn=a |drugClass=beta-lactam class of antibiotics |indicationType=treatment |indication='''1.1 Staphylococcus aureus Bloodstream Infection (Bacteremia)''' ZEVTERA is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infection (bacteremia) (SAB), including those with right-sided infective endocarditis, caused by me...")
  • 19:4819:48, 18 March 2025 Pegulicianine (hist | edit) [17,295 bytes] Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=User:AED |genericName=pegulicianine |aOrAn=a |drugClass=diagnostic imaging agent |indicationType=diagnosis |indication=LUMISIGHT is indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. |hasBlackBoxWarning=Yes |adverseReactions=*Anaphylaxis and Other Serious Hyp...")

17 March 2025

  • 18:3118:31, 17 March 2025 Air polymer-type A (hist | edit) [5,259 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Air polymer-type A intrauterine foam |aOrAn=an |drugClass=Ultrasound Contrast Agent |indication=sonohysterosalpingography to assess fallopian tube patency in women with known or suspected infertility. |adverseReactions=Pelvic and abdominal pain, Nausea and faintness, Post-procedure spotting |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="col...")
  • 15:3015:30, 17 March 2025 Trikafta (hist | edit) [7,857 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Elexacaftor, Tezacaftor, and Ivacaftor |aOrAn=a |drugClass=Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator |indicationType=treatment |indication=cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based on clinical and/or in vitro data. If the patient's genotype is unkn...")
  • 14:5814:58, 17 March 2025 Fluorodopa F 18 (hist | edit) [4,778 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=fluorodopa F 18 |aOrAn=a |drugClass=Radiopharmaceutical Diagnostic Agent |indication=indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). |adverseReactions=Injection site pain |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarn...")

14 March 2025

  • 10:3510:35, 14 March 2025 Brolucizumab–dbll (hist | edit) [6,665 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Brolucizumab-dbll |aOrAn=a |drugClass=Vascular Endothelial Growth Factor (VEGF) Inhibitor |indicationType=treatment |indication=Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) |adverseReactions=Vision blurred, Cataract, Conjunctival hemorrhage, Eye pain, and Vitreous floaters. |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWa...")

13 March 2025

  • 22:0122:01, 13 March 2025 Trifarotene (hist | edit) [4,963 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Trifarotene |aOrAn=a |drugClass=retinoid |indicationType=treatment |indication=acne vulgaris in patients 9 years of age and older |adverseReactions=Application site irritation, Application site pruritus (itching), Sunburn |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Trifarotene in adult patients. |offLabelAdultNoGuideSupport=There is lim...")

12 March 2025

  • 21:3721:37, 12 March 2025 Tenapanor (hist | edit) [4,276 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Tenapanor |aOrAn=a |drugClass=Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitor |indicationType=treatment |indication=irritable bowel syndrome with constipation (IBS-C) in adults. Also it v=can be used for reduction of serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy. |hasBlackBoxWarning=Yes |adverseReactions=Diarrhea (16% in IBS-C patients; 43-53% in CKD patien...")
  • 21:2021:20, 12 March 2025 Istradefylline (hist | edit) [4,113 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=istradefylline |aOrAn=an |drugClass=Adenosine A₂A Receptor Antagonist |indicationType=treatment |indication=adult patients with Parkinson's disease (PD) experiencing "off" episodes along with treatment to levodopa/carbidopa |adverseReactions=Dyskinesia (involuntary muscle movements), Hallucinations Insomnia, Nausea, and Constipation. |offLabelAdultGuideSupport=There is limited information regard...")

9 March 2025

  • 21:1921:19, 9 March 2025 Ga-68-DOTATOC (hist | edit) [4,233 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Gallium-68 DOTATOC |aOrAn=a |drugClass=radiopharmaceutical diagnostic agent |indicationType=procedure |indication=positron emission tomography (PET) imaging for the localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adult and pediatric patients. |adverseReactions=Nausea, Vomiting, Flushing, Injection site pain |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</...")
  • 21:0321:03, 9 March 2025 Lefamulin (hist | edit) [6,506 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Lefamulin |aOrAn=a |drugClass=Pleuromutilin Antibiotic |indicationType=treatment |indication=adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms. |adverseReactions=injection: administration site reactions, hepatic enzyme elevation, nausea, hypokalemia, insomnia, headache.​ Oral: diarrhea, nausea, vomiting, hepatic enzyme elevation. |blackBoxWarningTit...")
  • 20:4720:47, 9 March 2025 Upadacitinib (hist | edit) [9,728 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Upadacitinib |aOrAn=a |drugClass=Janus Kinase (JAK) Inhibitor |indicationType=treatment |indication=Moderate to severe active rheumatoid arthritis, Active psoriatic arthritis, Moderate to severe atopic dermatitis, Moderate to severe ulcerative colitis, Moderate to severe active Crohn's disease, Active ankylosing spondylitis, and Active non-radiographic axial spondyloarthritis. |hasBlackBoxWarning=Y...")
  • 20:3020:30, 9 March 2025 Fedratinib (hist | edit) [6,628 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Fedratinib |aOrAn=a |drugClass=Janus Kinase 2 (JAK2) Inhibitor |indicationType=treatment |indication=adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). |hasBlackBoxWarning=Yes |adverseReactions=Diarrhea, Nausea, Vomiting, Fatigue, Anemia, Thrombocytopenia, Elevated liver enzymes (ALT/AST), and Elevated...")
Retrieved from "https://www.wikidoc.org/index.php/Special:NewPages"